Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an intergroup trial

Patrick J. Loehrer, Kyungmann Kim, Seena C. Aisner, Robert Livingston, Lawrence H. Einhorn, David Johnson, Ronald Blum

Research output: Contribution to journalArticlepeer-review

225 Scopus citations

Abstract

Purpose: The purpose of this study was to evaluate the impact of cisplatin, doxorubicin, and cyclophosphamide (PAC) in patients with advanced thymoma with respect to response rate, duration of remission, and overall survival. Patients and Methods: Assessable patients with thymoma (n = 29) or thymic carcinoma (n = 1) with metastatic or locally progressive recurrent disease following radiotherapy were treated with intravenous cisplatin (50 mg/m2), doxorubicin (50 mg/m2), and cyclophosphamide (500 mg/m2) with normal saline hydration. Courses were repeated every 3 weeks for a maximum of eight cycles of therapy. Results: Toxicity, which was primarily hematologic, was mild, with only one patient developing a fever associated with neutropenia. Three complete responses (CRs) and 12 partial responses (PRs) were observed (CR + PR rate, 50%; 95% confidence interval, 31.3% to 68.7%). Ten patients had stable disease. The median duration of response was 11.8 months (range, 0.9 to 70.5+), the time to treatment failure 18.4 months (range, 0.8 to 91.9+), and median survival time 37.7 months (range, 2 to 91.9+). Conclusion: This trial demonstrates that objective response rates and prolonged survival can be achieved in patients with advanced thymoma.

Original languageEnglish (US)
Pages (from-to)1164-1168
Number of pages5
JournalJournal of Clinical Oncology
Volume12
Issue number6
DOIs
StatePublished - Jun 1994

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an intergroup trial'. Together they form a unique fingerprint.

Cite this